Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1159/000265937 | DOI Listing |
Int Urol Nephrol
January 2025
Nephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Introduction: Kidney transplantation is the preferred treatment for end-stage kidney disease (ESKD), enhancing survival and quality of life. However, kidney transplant recipients (KTRs) are at high risk for bone disorders, particularly low bone turnover disease, which increases fracture risk. Teriparatide, an anabolic agent, may provide a beneficial treatment option for these patients.
View Article and Find Full Text PDFJ Sex Med
January 2025
Department of Surgery, Section of Urology, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, United States.
Background: Understanding patient goals for metoidioplasty and phalloplasty gender-affirming surgery (MaPGAS) is paramount to achieving satisfactory, preference-sensitive outcomes, yet there is a lack of understanding of MaPGAS priorities and how these may vary between transgender men and non-binary individuals assigned female at birth (AFAB).
Aim: To understand the surgical goals of transgender men and non-binary individuals AFAB considering MaPGAS.
Methods: An online survey was created following literature review and qualitative interviews and distributed via social media and a community health center to participants AFAB aged ≥18 years who had considered but not yet undergone MaPGAS.
Lancet Diabetes Endocrinol
January 2025
Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA. Electronic address:
The hypothalamic-pituitary-thyroid axis plays a crucial role in the pathogenesis, diagnosis, risk stratification, effectiveness of radioiodine therapy, and treatment response evaluation in epithelial thyroid cancer. Supraphysiological doses of levothyroxine are used in patients with intermediate-risk and high-risk thyroid cancer to suppress thyroid-stimulating hormone (TSH) to prevent tumour progression. However, free thyroxine and tri-iodothyronine have also been found to promote tumour growth in thyroid cancer preclinical models.
View Article and Find Full Text PDFLancet Diabetes Endocrinol
January 2025
School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct effects of these drugs is the subject of intense interest. Although reductions in major adverse cardiovascular events appear to be predominantly driven by the direct tissue effects of such drugs, the associated weight loss effects must be relevant to the benefits observed in other major outcomes, albeit to differing extents. In this Personal View, we draw on evidence to support that weight loss is at least partly responsible (albeit to differing extents) for the reported benefits of incretin-based drugs for obesity in people living with heart failure with preserved ejection fraction, hypertension, chronic kidney disease, and type 2 diabetes.
View Article and Find Full Text PDFAnn Intern Med
January 2025
Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California (A.B., K.J.C., A.A.K.).
Background: Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) differ in their effects on body weight and risk for reoperation. However, it is unclear whether long-term health expenditures differ by procedure type in patients with diabetes.
Objective: To compare health expenditures 3 years before and 5.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!